Seller record · Telehealth service

T2D Com

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home page and the about page refer only to pharmacy partners and licensed pharmacies the company contracts with. 2 more criteria also fail; see the table below.

At a glance

T2D ComTelehealth service

4/8criteria passed

Price: Compounded semaglutide or tirzepatide $170 a month with the prescriber, medication and delivery included
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: None on file

Visit T2D Com See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A subscription service for type 2 diabetes, pre-diabetes and weight loss that bundles a prescriber, compounded semaglutide or tirzepatide and home delivery into one monthly fee, and also fills outside prescriptions for compounded semaglutide.

Operating entity T2D Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	T2D Com's website; T2D Com's weight loss page
S2	Prescription gating	NOT VERIFIED	T2D Com's website; T2D Com's terms of service page
S3	Pharmacy identification	FAIL	T2D Com's website; T2D Com's about page
S4	Compounding disclosure	FAIL	T2D Com's compounded tirzepatide page; T2D Com's weight loss page; T2D Com's Ozempic and compounded semaglutide page
S5	Analytical documentation	FAIL	T2D Com's website; T2D Com's weight loss page; T2D Com's compounded semaglutide page
S6	Business address	PASS	T2D Com's privacy policy; T2D Com's terms of service page
S7	Price disclosure	PASS	T2D Com's weight loss page; T2D Com's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed prescriber included in the service evaluates each member and decides the medication and dose before anything is prepared, with ongoing monitoring after. No prescriber is named.Source: T2D Com's website; T2D Com's weight loss page.

S2NOT VERIFIEDWhether payment is taken before the medical evaluation did not resolve, because the steps list registering with basic information first and the prescriber's evaluation second, while the terms say the monthly fee is charged on the date the subscription is purchased. The check is open.Source: T2D Com's website; T2D Com's terms of service page.

S3FAILNo filling pharmacy is named. The home page and the about page refer only to pharmacy partners and licensed pharmacies the company contracts with.Source: T2D Com's website; T2D Com's about page.

S4FAILThe compounded tirzepatide safety page describes tirzepatide as FDA-approved for type 2 diabetes, and the home and weight-loss pages sell compounded semaglutide and tirzepatide with no statement that they are not FDA-approved. Only a knowledge-base article says compounded semaglutide has not been through FDA approval.Source: T2D Com's compounded tirzepatide page; T2D Com's weight loss page; T2D Com's Ozempic and compounded semaglutide page.

S5FAILNo certificate of analysis or lot document is published on the home page, the weight-loss page, the safety pages or the terms.Source: T2D Com's website; T2D Com's weight loss page; T2D Com's compounded semaglutide page.

S6PASST2D Inc. at Suite 232, 1350 Ave of Americas, New York, NY 10019, printed twice in the privacy policy. The terms name T2D Inc., a Delaware corporation, and Delaware law.Source: T2D Com's privacy policy; T2D Com's terms of service page.

S7PASSThe service with a prescriber costs $170 a month, all-inclusive, with compounded semaglutide or tirzepatide, the prescriber, support and delivery. Members who bring their own prescription pay $99 a month for compounded semaglutide at 0.25 or 0.50 mg, printed beside a struck-through $170.Source: T2D Com's weight loss page; T2D Com's website.

S8PASSNo FDA warning letter names T2D or T2D Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit T2D Com

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.